CBPO [China Biologic Products] PRER14A:
[]
CBPO [China Biologic Products] 8-K: (Original Filing)
[CHINA BIOLOGIC PRODUCTS, INC. DIRECTOR AGREEMENT Agreement Company Mr. Dai Feng Director THIS AGREEMENT (The “ BACKGROUND The Board of Directors of the Company desires to appoint the Director to fill an existing vacancy due to resignation of Dr. Bing Li and to have the Director perform the duties of a director and the Director desires to be so appointed] []
CBPO [China Biologic Products] 8-K: (Original Filing)
[FOR RELEASE May 6, 2014 China Biologic Reports Financial Results for the First Quarter of 2014 1Q14 Total Sales Increase 4.1% to $56.3Million 1Q14 Operating Margin Increases to 49.7% from 1Q14 Non-GAAP Net Income Increases 16.3% to $ 19.1Million BEIJING, China – May 6, 2014 – First Quarter 2014 Financial Highlights · Total sales · Gross profit · Income from] []
CBPO [China Biologic Products] 8-K: FOR RELEASE May 6, 2014 China Biologic Reports
[FOR RELEASE May 6, 2014 China Biologic Reports Financial Results for the First Quarter of 2014 1Q14 Total Sales Increase 4.1% to $56.3Million 1Q14 Operating Margin Increases to 49.7% from 1Q14 Non-GAAP Net Income Increases 16.3% to $ 19.1Million BEIJING, China – May 6, 2014 – First Quarter 2014 Financial Highlights · Total sales · Gross profit · Income from] []
CBPO [China Biologic Products] 10-Q: (Original Filing)
[] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial Officer)]
CBPO [China Biologic Products] 10-Q:
[] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial Officer)]
CBPO [China Biologic Products] DEFA14A: (Original Filing)
[SCHEDULE 14A x ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material under Rule 14a-12 CHINA BIOLOGIC PRODUCTS, INC. ________________________________________________________ Payment of Filing Fee (Check the appropriate box): x No fee required ¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of]
CBPO [China Biologic Products] 8-K: (Original Filing)
[FOR RELEASE March 12, 2014 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2013 -- FY13 Total Sales Up 10.0% to $203.4 Million -- -- FY13 Operating Margin Up 240 Basis Points to 42.7% -- -- FY13 Non-GAAP Net Income Up 22.9% to $59.0 Million -- -- Issues FY14 Forecast -- BEIJING, China – March 12,] []
CBPO [China Biologic Products] 8-K: FOR RELEASE March 12, 2014 China Biologic Reports
[FOR RELEASE March 12, 2014 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2013 -- FY13 Total Sales Up 10.0% to $203.4 Million -- -- FY13 Operating Margin Up 240 Basis Points to 42.7% -- -- FY13 Non-GAAP Net Income Up 22.9% to $59.0 Million -- -- Issues FY14 Forecast -- BEIJING, China – March 12,] []
